Bioxcel therapeutics announces positive full data from phase 2 trial of bxcl701 in rare, aggressive form of prostate cancer; to be presented at 2023 asco genitourinary cancers symposium

Bxcl701 plus keytruda® (pembrolizumab) demonstrated composite response rate of 25% in patients with metastatic scnc-variant castration-resistant prostate cancer
BTAI Ratings Summary
BTAI Quant Ranking